Cargando…
Intraperitoneal Delivery of Iopamidol to Assess Extracellular pH of Orthotopic Pancreatic Tumor Model by CEST-MRI
The extracellular pH (pHe) of solid tumors is often acidic, as a consequence of the Warburg effect, and an altered metabolic state is often associated with malignancy. It has been shown that acidosis can promote tumor progression; thus, many therapeutic strategies have been adopted against tumor met...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9836819/ https://www.ncbi.nlm.nih.gov/pubmed/36704211 http://dx.doi.org/10.1155/2023/1944970 |
_version_ | 1784868943311142912 |
---|---|
author | Jardim-Perassi, Bruna Victorasso Irrera, Pietro Lau, Justin Y. C. Budzevich, Mikalai Whelan, Christopher J. Abrahams, Dominique Ruiz, Epifanio Ibrahim-Hashim, Arig Damgaci Erturk, Sultan Longo, Dario Livio Pilon-Thomas, Shari A. Gillies, Robert J. |
author_facet | Jardim-Perassi, Bruna Victorasso Irrera, Pietro Lau, Justin Y. C. Budzevich, Mikalai Whelan, Christopher J. Abrahams, Dominique Ruiz, Epifanio Ibrahim-Hashim, Arig Damgaci Erturk, Sultan Longo, Dario Livio Pilon-Thomas, Shari A. Gillies, Robert J. |
author_sort | Jardim-Perassi, Bruna Victorasso |
collection | PubMed |
description | The extracellular pH (pHe) of solid tumors is often acidic, as a consequence of the Warburg effect, and an altered metabolic state is often associated with malignancy. It has been shown that acidosis can promote tumor progression; thus, many therapeutic strategies have been adopted against tumor metabolism; one of these involves alkalinization therapies to raise tumor pH to inhibit tumor progression, improve immune surveillance, and overcome resistance to chemotherapies. Chemical exchange saturation transfer-magnetic resonance imaging (CEST-MRI) is a noninvasive technique that can measure pH in vivo using pH-sensitive contrast agents. Iopamidol, an iodinated contrast agent, clinically used for computed tomography (CT), contains amide group protons with pH-dependent exchange rates that can reveal the pHe of the tumor microenvironment. In this study, we optimized intraperitoneal (IP) delivery of iopamidol to facilitate longitudinal assessments of orthotopic pancreatic tumor pHe by CEST-MRI. Following IV-infusion and IP-bolus injections, we compared the two protocols for assessing tumor pH. Time-resolved CT imaging was used to evaluate the uptake of iopamidol in the tumor, revealing that IP-bolus delivered a high amount of contrast agent 40 min postinjection, which was similar to the amounts reached with the IV-infusion protocol. As expected, both IP and IV injection protocols produced comparable measurements of tumor pHe, showing no statistically significant difference between groups (p=0.16). In addition, we showed the ability to conduct longitudinal monitoring of tumor pHe using CEST-MRI with the IP injection protocol, revealing a statistically significant increase in tumor pHe following bicarbonate administration (p < 0.001). In conclusion, this study shows the capability to measure pHe using an IP delivery of iopamidol into orthotopic pancreatic tumors, which is important to conduct longitudinal studies. |
format | Online Article Text |
id | pubmed-9836819 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-98368192023-01-25 Intraperitoneal Delivery of Iopamidol to Assess Extracellular pH of Orthotopic Pancreatic Tumor Model by CEST-MRI Jardim-Perassi, Bruna Victorasso Irrera, Pietro Lau, Justin Y. C. Budzevich, Mikalai Whelan, Christopher J. Abrahams, Dominique Ruiz, Epifanio Ibrahim-Hashim, Arig Damgaci Erturk, Sultan Longo, Dario Livio Pilon-Thomas, Shari A. Gillies, Robert J. Contrast Media Mol Imaging Research Article The extracellular pH (pHe) of solid tumors is often acidic, as a consequence of the Warburg effect, and an altered metabolic state is often associated with malignancy. It has been shown that acidosis can promote tumor progression; thus, many therapeutic strategies have been adopted against tumor metabolism; one of these involves alkalinization therapies to raise tumor pH to inhibit tumor progression, improve immune surveillance, and overcome resistance to chemotherapies. Chemical exchange saturation transfer-magnetic resonance imaging (CEST-MRI) is a noninvasive technique that can measure pH in vivo using pH-sensitive contrast agents. Iopamidol, an iodinated contrast agent, clinically used for computed tomography (CT), contains amide group protons with pH-dependent exchange rates that can reveal the pHe of the tumor microenvironment. In this study, we optimized intraperitoneal (IP) delivery of iopamidol to facilitate longitudinal assessments of orthotopic pancreatic tumor pHe by CEST-MRI. Following IV-infusion and IP-bolus injections, we compared the two protocols for assessing tumor pH. Time-resolved CT imaging was used to evaluate the uptake of iopamidol in the tumor, revealing that IP-bolus delivered a high amount of contrast agent 40 min postinjection, which was similar to the amounts reached with the IV-infusion protocol. As expected, both IP and IV injection protocols produced comparable measurements of tumor pHe, showing no statistically significant difference between groups (p=0.16). In addition, we showed the ability to conduct longitudinal monitoring of tumor pHe using CEST-MRI with the IP injection protocol, revealing a statistically significant increase in tumor pHe following bicarbonate administration (p < 0.001). In conclusion, this study shows the capability to measure pHe using an IP delivery of iopamidol into orthotopic pancreatic tumors, which is important to conduct longitudinal studies. Hindawi 2023-01-05 /pmc/articles/PMC9836819/ /pubmed/36704211 http://dx.doi.org/10.1155/2023/1944970 Text en Copyright © 2023 Bruna Victorasso Jardim-Perassi et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Jardim-Perassi, Bruna Victorasso Irrera, Pietro Lau, Justin Y. C. Budzevich, Mikalai Whelan, Christopher J. Abrahams, Dominique Ruiz, Epifanio Ibrahim-Hashim, Arig Damgaci Erturk, Sultan Longo, Dario Livio Pilon-Thomas, Shari A. Gillies, Robert J. Intraperitoneal Delivery of Iopamidol to Assess Extracellular pH of Orthotopic Pancreatic Tumor Model by CEST-MRI |
title | Intraperitoneal Delivery of Iopamidol to Assess Extracellular pH of Orthotopic Pancreatic Tumor Model by CEST-MRI |
title_full | Intraperitoneal Delivery of Iopamidol to Assess Extracellular pH of Orthotopic Pancreatic Tumor Model by CEST-MRI |
title_fullStr | Intraperitoneal Delivery of Iopamidol to Assess Extracellular pH of Orthotopic Pancreatic Tumor Model by CEST-MRI |
title_full_unstemmed | Intraperitoneal Delivery of Iopamidol to Assess Extracellular pH of Orthotopic Pancreatic Tumor Model by CEST-MRI |
title_short | Intraperitoneal Delivery of Iopamidol to Assess Extracellular pH of Orthotopic Pancreatic Tumor Model by CEST-MRI |
title_sort | intraperitoneal delivery of iopamidol to assess extracellular ph of orthotopic pancreatic tumor model by cest-mri |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9836819/ https://www.ncbi.nlm.nih.gov/pubmed/36704211 http://dx.doi.org/10.1155/2023/1944970 |
work_keys_str_mv | AT jardimperassibrunavictorasso intraperitonealdeliveryofiopamidoltoassessextracellularphoforthotopicpancreatictumormodelbycestmri AT irrerapietro intraperitonealdeliveryofiopamidoltoassessextracellularphoforthotopicpancreatictumormodelbycestmri AT laujustinyc intraperitonealdeliveryofiopamidoltoassessextracellularphoforthotopicpancreatictumormodelbycestmri AT budzevichmikalai intraperitonealdeliveryofiopamidoltoassessextracellularphoforthotopicpancreatictumormodelbycestmri AT whelanchristopherj intraperitonealdeliveryofiopamidoltoassessextracellularphoforthotopicpancreatictumormodelbycestmri AT abrahamsdominique intraperitonealdeliveryofiopamidoltoassessextracellularphoforthotopicpancreatictumormodelbycestmri AT ruizepifanio intraperitonealdeliveryofiopamidoltoassessextracellularphoforthotopicpancreatictumormodelbycestmri AT ibrahimhashimarig intraperitonealdeliveryofiopamidoltoassessextracellularphoforthotopicpancreatictumormodelbycestmri AT damgacierturksultan intraperitonealdeliveryofiopamidoltoassessextracellularphoforthotopicpancreatictumormodelbycestmri AT longodariolivio intraperitonealdeliveryofiopamidoltoassessextracellularphoforthotopicpancreatictumormodelbycestmri AT pilonthomassharia intraperitonealdeliveryofiopamidoltoassessextracellularphoforthotopicpancreatictumormodelbycestmri AT gilliesrobertj intraperitonealdeliveryofiopamidoltoassessextracellularphoforthotopicpancreatictumormodelbycestmri |